Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22784329 | 0.81 | TSHR (0.33) | TSHR | |
| Hydrochloric Acid SCHEMBL22776308 | 0.79 | TSHR (0.33) | SMN1; SMN2TSHR | |
| SCHEMBL8886486 | 0.76 | — | — | |
| SCHEMBL15499299 | 0.72 | — | — | |
| SCHEMBL26465285 | 0.72 | BRD4 (0.58) | BRD4SMN1; SMN2LTA4HTSHR | |
| SCHEMBL10280096 | 0.72 | BRD4 (0.53) | BRD4SMN1; SMN2LTA4HSLC6A2SLC6A4 | |
| SCHEMBL14524250 | 0.70 | EPHX2 (0.38) | BRD4TSHR | |
| SCHEMBL2864044 | 0.69 | BRD4 (0.50) | BRD4SMN1; SMN2LTA4HSLC6A2SLC6A4 | |
| SCHEMBL10211760 | 0.69 | BRD4 (0.46) | BRD4SMN1; SMN2LTA4HTSHR | |
| SCHEMBL13189158 | 0.69 | BRD4 (0.50) | BRD4SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950477-A | Modulators of progranulin and methods of use thereof | 阿库达医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | BRD4 2446/4885SMN1; SMN2 644/4885LTA4H 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.